StockMarketWire.com - Diurnal Group said its adrenal insufficiency treatment had been been granted Orphan Drug Designation in Australia.

'Orphan Drug Designation in Australia provides significant benefits, including waiver of application, evaluation and annual registration fees,' the company said.

Separately, Diurnal said its second patent for Alkindi in Australia, No: 2014267041 entitled "Composition Comprising Hydrocortisone", had been granted.




At 9:35am: [LON:DNL] Diurnal Group Plc share price was +4p at 31p



Story provided by StockMarketWire.com